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TO THE EDITOR
Individuals with rosacea express high
baseline levels of cathelicidin and kal-
likrein 5 (KLK5; Yamasaki et al., 2007).
The significance of elevated KLK5 is that
this trypsin-like serine protease controls
the cleavage of the cathelicidin precur-
sor protein into LL-37 (Yamasaki et al.,
2006, 2007). LL-37 is both proinflam-
matory and angiogenic (Koczulla et al.,
2003; Lande et al., 2007; Morizane
et al., 2012). Based on these findings,
we hypothesized that inhibition of KLK5
may improve the clinical signs of ro-
sacea by decreasing LL-37 production.
To test this hypothesis, we studied the
effects of a known inhibitor of trypsin-
like serine protease, e-aminocaproic
acid (ACA). ACA is Food and Drug
Administration approved for systemic
administration to enhance hemostasis
in cases of fibrinolytic bleeding, and is
well-tolerated in humans when adminis-
tered intravenously in doses up to
3 g kg1. To determine whether ACA
might be useful in rosacea, ACA was
first tested in vitro using an Enzcheck
Protease Assay Kit (Invitrogen) against
the proteolytic activity of tissue
kallikrein (100mg ml1, Sigma-Aldrich,
St Louis, MO) or stratum corneum pro-
tease activity (SPA) collected from tape-
strips (D-100 CuDerm, Dallas, TX) of
the facial skin of six healthy subjects.
SPA was extracted from tape with 20 mM
Tris-HCl (pH 8.0) containing 0.1%
Triton X-100. Protease activity was
measured at 37 1C for 2 hours after
treatment with vehicle, ACA (1 M), or
the known selective inhibitor of trypsin-
related enzymes, aprotinin (50mg ml1,
Sigma-Aldrich). Aprotinin strongly sup-
pressed SPA, indicating predominance
of trypsin-like proteases in the stratum
corneum extract. The inhibitory effect of
ACA was similar to that of aprotinin
(Figure 1). These combined data sug-
gested that ACA could be effective to
inhibit stratum corneum trypsin-like pro-
teases such as KLK5.
Having confirmed that ACA was an
effective inhibitor of SPA in vitro, we
next sought to determine whether topi-
cal application of a cream formulation
containing equal weight of cream and
ACA solution (2 M) decreased SPA in
patients with rosacea. If active, this
formulation, called SEI003, would per-
mit us to test the hypothesis that inhibi-
tion of SPA improves rosacea. We
therefore conducted a proof-of-concept,
randomized, double-blind, placebo-
controlled study on 11 adult patients
with papulopustular rosacea (clinical-
trials.gov identifier NCT01398280).
The study was conducted at the Uni-
versity of California, San Diego (UCSD)
dermatology clinic in accordance with
the Declaration of Helsinki Principles
and the regulations of the UCSD Institu-
tional Review Board (reference number
100867). Written informed consent was
obtained from all participants. The study
was conducted between July 2011 and
December 2012, and included 15 sub-
jects with papulopustular rosacea ran-
domized 2:1 to receive either SEI003
(the treatment group) or the base cream
homogenized with an equal weight of
the ACA vehicle (the placebo group).
Subjects, study coordinators, and those
performing clinical assessments were
blinded. Of the 11 patients originally
assigned to the treatment group, three
subjects voluntarily withdrew from the
study (one patient reported scheduling
conflicts and two others were no longer
interested in participating), and one was
withdrawn from the study after starting
doxycycline for ocular rosacea. The
study numbers of participants who with-
drew from the study were reassigned
to new subjects after patient 11 was
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Figure 1. In vitro effects of SEI003 and aprotinin on KLK and human total stratum corneum protease
activity. (a) Both SEI003 and aprotinin inhibit KLK activity compared to vehicle alone. SEI003 completely
blocks KLK activity for the first 45 minutes of the assay. (b) Compared to vehicle alone, SEI003 and
aprotinin both significantly decrease stratum corneum protease activity. KLK, kallikrein; RFU, relative
fluorescent units.
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enrolled. All four patients originally
assigned to the placebo group com-
pleted the study in its entirety. Patients
were instructed to apply their assigned
medication to their entire face twice
daily for the 12-week duration of the
study. Clinical assessments including
the Investigator’s Global Assessment
(IGA) and the summed total of the 5-
point Clinician’s Erythema Assessment
(CEA) score of five different target sites
(left cheek, right cheek, nose, chin, and
glabella), as well as digital photography
were completed at baseline. These
procedures were repeated 2, 6, 9, and
12 weeks after the baseline visit along
with safety monitoring and tape strip
sampling for SPA.
The average age and baseline IGA
and CEA scores for subjects in the two
groups were similar (Figure 2a). The
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Figure 2. Response of rosacea patients to SEI003 treatment. (a) Demographic data for participants completing the trial. (b) Stratum corneum protease activity (SPA)
levels were not significantly different in the treatment groups at week 2, however differences at weeks 6, 9, and 12 were statistically significant. (c) SPA levels of
individual subjects in the treatment group tended to decrease over time. (d) SPA levels of individual subjects in the placebo group remained relatively unchanged
over time. (e) IGA scores decreased throughout the study for participants in both groups, however scores were only significant for time and the interaction between
time and treatment group. (f) CEA scores also trended down as participants progressed through the study, however a two-way analysis of variance of CEA scores for
participants in both groups was significant only for time. (g) Decreased erythema is seen in patients in the treatment group at week 12. (h) Decreased erythema is also
appreciated in this control subject over time, however this finding is less pronounced in these patients. Error bars represent mean±SE of the mean. Treatment group
n¼ 7, control group n¼4. CEA, Clinician’s Erythema Assessment; IGA, Investigator’s Global Assessment; KLK, kallikrein; RFU, relative fluorescent units.
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average of the SEI003 treatment group
had significantly lower SPA compared
with the placebo group at weeks 6, 9,
and 12 after the start of therapy. A two-
way analysis of variance comparing the
SPA of subjects in the two groups at all
visits showed that treatment group
(P¼ 0.002), time (P¼0.002), and the
interaction between time and treatment
group (P¼0.001) all had a significant
effect on subjects’ SPA (Figure 2b). As
this was a small pilot study, and to better
illustrate the individual response of SPA
over the course of the study, SPA levels
were also plotted for each subject over
time. SPA levels of the two subjects with
the highest baseline SPA had the most
pronounced decrease (Figure 2c). In
contrast, SPA levels of subjects in the
placebo group remained relatively
stable during the course of the study
(Figure 2d).
Overall improvements in IGA and
CEA scores were seen in subjects in
both the placebo and SEI003 groups
over the 12-week course of the study.
Although there were no significant dif-
ferences in IGA and CEA scores
between the two groups at any time
point, a correlation between activity to
inhibit SPA and clinical improvement
was seen as IGA and CEA scores of
subjects in the SEI003 group differed
significantly at week 12 compared to
baseline (P¼0.05, Figure 2e and f). This
significant change was not seen in the
placebo group (P¼0.15, Figure 2e;
P¼0.98, Figure 2f). These findings are
likely related to the small sample size
and short duration of the study, as well
as a placebo effect from the base cream.
Digital photographs taken of partici-
pant’s faces at the beginning of each
visit showed the pronounced improve-
ment in rosacea symptoms in some
patients receiving SEI003 (Figure 2g
and h). Interestingly, the two subjects
with the highest baseline SPA values
were among the subjects with the most
noticeable changes on digital photogra-
phy, and both are pictured in Figure 2g.
No adverse events were reported during
the study.
Previous studies have correlated high
KLK5 activity with rosacea disease state
(Yamasaki et al., 2007). Recent studies
of known rosacea treatments suggest
that clinical improvements correlate
with decreases in this protease cas-
cade, suggesting that KLK5 has a key
role in mediating the inflammatory
response seen in rosacea by its ability
to activate cathelicidin. A recent open-
label study of 15% azelaic acid gel
showed that rosacea patients with high
baseline SPA had a significant reduction
in their SPA by week 16 of treatment,
and this correlated with clinical impro-
vement (Coda et al., 2013). Our data
show a similar trend, with subjects with
the highest baseline SPA correlating
with maximal improvement. In another
recent study, the antibiotic doxycycline
was found to indirectly inhibit SPA and
block LL-37 generation in vitro (Kanada
et al., 2012). Subsequently, a report of a
multi-center clinical trial showed that
the therapeutic benefits of doxycycline
when taken as a formulation consisting
of both immediate release and delayed
release beads also correlated with
decreased protease activity and LL-37
(Huang et al., 2013). Our study agrees
with the associations observed in these
other studies, and further suggests that
direct targeted inhibition of SPA can
result in a reduction of erythema and
inflammatory papules in some patients
with rosacea.
In conclusion, this pilot study shows
early clinical evidence that directly sup-
ports a causative role for high protease
activity in the pathogenesis of rosacea.
Although we failed to show clear evi-
dence of clinical benefit over placebo
for this formulation of serine protease
inhibitor, this study was designed only
as a proof-of-concept trial with a small
number of patients. This work supports
the KLK-cathelicidin inflammation
hypothesis and the need for adequately
powered clinical trial of the therapeutic
benefit of direct targeting of SPA in the
treatment and control of rosacea.
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